Get the Stockscreener App
6.43
1.26%
0.08
After Hours:
6.47
0.04
+0.62%
Nyxoah Sa stock is traded at $6.43, with a volume of 79,929.
It is up +1.26% in the last 24 hours and down -17.56% over the past month.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
See More
Previous Close:
$6.35
Open:
$6.28
24h Volume:
79,929
Relative Volume:
0.85
Market Cap:
$245.99M
Revenue:
$4.71M
Net Income/Loss:
$-46.77M
P/E Ratio:
-3.8292
EPS:
-1.6792
Net Cash Flow:
$-60.34M
1W Performance:
+3.38%
1M Performance:
-17.56%
6M Performance:
-37.86%
1Y Performance:
-20.81%
1-Day Range:
$6.28
$6.60
1-Week Range:
$6.02
$6.85
52-Week Range:
$5.55
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
Name
Nyxoah Sa
Sector
Industry
Phone
-
Address
-
Compare NYXH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
6.43 | 245.99M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
476.16 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
199.66 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
82.02 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
293.73 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
247.85 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-21-22 | Initiated | Oppenheimer | Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Dec-21-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-28-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Nyxoah Sa Stock (NYXH) Latest News
Nyxoah sees Q2 revenue up 73%, plans R&D shift to U.S. and Belgium; shares rise - MSN
Price Channel Expanding on Nyxoah SA’s Chart2025 EndofYear Setup & AI Powered Market Entry Strategies - classian.co.kr
Nyxoah: The High-Risk High-Reward Medtech To Own (NASDAQ:NYXH) - Seeking Alpha
Brainstorm Posts 43% EPS Gain in Q2 - AOL.com
Oncology Institute Sales Jump 22 Percent - AOL.com
Vivos Therapeutics Unveils New Model - AOL.com
Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift - AOL.com
UroGen (URGN) Q2 Revenue Rises 11% - AOL.com
Nyxoah total operating loss for Q2 2025 hits €19.9M - Medical Buyer
Oppenheimer reiterates Outperform rating on Nyxoah stock with $13 target - Investing.com
Stifel reiterates Buy rating on Nyxoah stock following FDA approval - Investing.com
NewAmsterdam (NAMS) Q2 Revenue Jumps 49% - AOL.com
Nyxoah’s Genio System Gains FDA Approval - TipRanks
Nyxoah's FDA Approval and U.S. Launch of Genio System: A High-Conviction Play in the OSA Market? - AInvest
Earnings call transcript: Nyxoah Q2 2025 sees stock rise post-earnings By Investing.com - Investing.com Nigeria
Nyxoah Q2 Revenue Jumps 74 Percent - AOL.com
NeuroPace Revenue Jumps 22 Percent in Q2 - AOL.com
Nyxoah's Q2 2025: Unpacking Key Contradictions in Commercial Launch, Reimbursement, and Regulatory Strategies - AInvest
Earnings call transcript: Nyxoah Q2 2025 sees stock rise post-earnings - Investing.com
Nyxoah (NYXH) Q2 2025 Earnings Call Transcript - Mitrade
Nyxoah Q2 2025 Earnings Call Transcript - MarketBeat
Nyxoah Q2 Revenue Jumps 74 Percent - The Motley Fool
Nyxoah Launches Genio System in U.S. Following FDA Approval - TipRanks
Nyxoah SA reports results for the quarter ended June 30Earnings Summary - TradingView
Nyxoah Reports Second Quarter Financial and Operating Results - The Manila Times
First-Ever Bilateral Sleep Apnea Neurostimulation Device: Nyxoah's Genio Gets FDA Green Light with 67% Efficacy - Stock Titan
Nyxoah : Q2 Report 2025 - MarketScreener
Can Traders Expect Breakout From Nyxoah SA This WeekJuly 2025 Market Mood & Weekly Top Gainers Alerts - newsimpact.co.kr
Market reaction to Nyxoah SA’s recent newsBond Market & Capital Efficiency Focused Ideas - Newser
Visualizing Nyxoah SA stock with heatmapsQuarterly Market Summary & Stepwise Swing Trade Plans - Newser
Will Nyxoah SA benefit from macro trendsPortfolio Update Summary & Risk Managed Trade Strategies - Newser
How to read the order book for Nyxoah SAPortfolio Gains Report & Verified Stock Trade Ideas - Newser
Will Nyxoah SA be affected by tariffsTrade Signal Summary & Technical Analysis for Trade Confirmation - mustnews.co.kr
Nyxoah SA stock momentum explained2025 Price Momentum & Weekly High Potential Alerts - Newser
Using data filters to optimize entry into Nyxoah SA2025 Biggest Moves & Community Trade Idea Sharing Platform - Newser
Will Nyxoah SA announce a stock splitJuly 2025 Technicals & AI Enhanced Market Trend Forecasts - thegnnews.com
Smart tools for monitoring Nyxoah SA’s price actionTrade Exit Summary & Expert Curated Trade Ideas - Newser
Adagio Medical Posts Narrower Q2 Loss - AOL.com
Is Nyxoah SA forming a reversal patternWeekly Gains Report & Smart Swing Trading Techniques - Newser
Nyxoah Secures FDA Approval for Innovative Sleep Apnea Treatment - AInvest
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea - Yahoo Finance
What drives Nyxoah SA’s stock priceQuarterly Trade Report & Verified Short-Term Plans - mustnews.co.kr
Nyxoah SA Uptrend in Early Stages Indicators Say YesWeekly Profit Recap & Real-Time Volume Triggers - newsyoung.net
What’s the recovery path for long term holders of Nyxoah SAQuarterly Profit Review & AI Based Buy and Sell Signals - Newser
Top chart patterns to watch in Nyxoah SAEarnings Risk Report & Detailed Earnings Play Alerts - Newser
Verrica Posts Profit in Fiscal Q2 - AOL.com
Adaptimmune Sales Jump 59 Percent - AOL.com
Citius Oncology Beats Fiscal Q3 EPS - AOL.com
When is the best time to buy Nyxoah SA stockWeekly Trade Review & Reliable Trade Execution Plans - Newser
Nyxoah wins FDA approval for Genio OSA treatment - BioWorld MedTech
Nyxoah Gains FDA Approval for Genio System, Reports 73% Revenue Increase in Q2 2025. - AInvest
Nyxoah Sa Stock (NYXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):